Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug

OBJECTIVES: Patients on anti-tuberculosis therapy (ATT) are more prone to drug interactions in the presence of coexisting illnesses which warrant drug therapy. Rifampicin is a strong CYP enzyme inducer while isoniazid is a potent CYP inhibitor. The objective of the study was to find the net effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Melvin, Shewade, Deepak Gopal, Kumar, Saka Vinod, Adithan, Chandrasekaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469952/
https://www.ncbi.nlm.nih.gov/pubmed/23087510
http://dx.doi.org/10.4103/0253-7613.99314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469952/
https://www.ncbi.nlm.nih.gov/pubmed/23087510
http://dx.doi.org/10.4103/0253-7613.99314

Ejemplares similares